New test for accurate differentiation of stroke types launched at Goodwood FOS Future Lab
A ground-breaking new test which improves the accuracy of stroke diagnosis has been developed by Randox scientists.
The rapid and highly sensitive blood test, which is due to be unveiled at this year’s Goodwood Festival of Speed, can uniquely differentiate between ischaemic strokes (a blood clot) and haemorrhagic strokes (a bleed) and subsequently enable clinicians to rapidly administer the most effective treatment, which is a vital factor in limiting permanent damage.
What’s even more remarkable is that the pioneering diagnostic, appearing as part of the festival’s Future Lab exhibition, takes less than 30 minutes to complete – making sure patients get the right diagnosis as fast as possible.
Dr Peter FitzGerald, Managing Director of Randox Laboratories, whose team developed the test, commented;
“There is great tragedy in the fact that the majority of stroke damage can be minimised if intervention is delivered on time, yet too often the window closes before a diagnosis is made. For doctors, nothing is more frustrating.
“Excellent work has been undertaken to assist the public in recognising the signs of a stroke so people can get to hospital as quickly as possible. Our stroke test is the vital next step – assisting clinicians in making a rapid diagnosis and differentiation between haemorrhagic and ischaemic stroke, so their patients get the right treatment at the right time.”
Traditionally the first step in a stroke diagnosis is a CT scan, which, despite its ability to successfully diagnose haemorrhagic stroke, is significantly less capable of identifying ischaemic stroke.
Yet ischaemic stroke is the most common type of stroke and affects almost nine in ten patients. Its diagnosis and differentiation from haemorrhagic stroke is vital in enabling thrombolytic treatment to break down blood clots, which, given its nature, could be fatal if administered to a patient suffering from a haemorrhagic stroke. Worryingly though, in some areas of the UK, as little as 15% of eligible stroke patients receive this therapy in time.1
This is caused by a number of factors, including difficulty in determining stroke onset time, exceeding the appropriate time window for thrombolysis administration (4.5 hours from stroke onset), and importantly, not being able to differentiate ischaemic stroke from a number of other ‘stroke mimics’ including severe migraine, brain tumours, drug overdose and seizures.
The Randox Stroke Biochip successfully identifies ischaemic stroke in a rapid test which measures eight markers from a single blood sample simultaneously, in just 30 minutes.
John Lamont, R&D Director for Randox Laboratories, explained;
“While patients undergo a CT scan to confirm either the presence or lack of a haemorrhagic stroke, a blood test on the Randox Biochip can be run on our innovative point-of-care analyser, the MultiSTAT, to identify the same for an ischaemic stroke.
“For the almost 90% of stroke patients who are ruled out for haemorrhagic stroke2, the Randox Biochip will then accelerate decision making for clinicians with regards to thrombolytic therapy.
“Any treatment is most effective if started as soon as possible after the stroke occurs, and so every minute that passes without a diagnosis is likely to leave a permanent mark on a stroke patient’s future health and lifestyle. The vitally important diagnostic information from the Randox Stroke Biochip facilitates accurate stroke classification, directs the appropriate patient care pathway, and enables rapid thrombolytic therapy, ensuring a better patient outcome for ischaemic stroke sufferers, for whom time is of the essence.”
Whilst the Randox Stroke Biochip is currently being used as complementary testing in parallel with CT scanning, Mr Lamont is confident of a more prominent role for the test in the future patient pathway;
“The Biochip has the potential to really revolutionise the stroke diagnosis pathway as we currently know it. The accessibility of this type of blood testing could potentially extend its use beyond the A&E department, to ambulances and even the home, in the form of a hand-held testing device.”
For further information about our pioneering new stroke test, or about the Goodwood Festival of Speed Future Lab, please contact Amy McIlwaine in the Randox PR team by emailing firstname.lastname@example.org
1 Royal College of Physicians Sentinel Stroke National Audit Programme (SSNAP). Clinical audit Jan – Mar 2016 report prepared by Royal College of Physicians, Clinical Effectiveness and Evaluation Unit on behalf of the Intercollegiate Stroke Working Party.
2 Intercollegiate Stroke Working Party. National clinical guideline for stroke, 5th edition. London: Royal College of Physicians 2016.